• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Abbott rolls out National Diabetes Awareness Month initiative to promote CGM use

November 1, 2023 By Sean Whooley

Abbott Countdown at a Crossroads National Diabetes Awareness month initiative
The Countdown at a Crossroads initiative kicks off this month. [Image courtesy of Abbott]
Abbott (NYSE:ABT) announced today that it launched its new “Countdown at a Crossroads” initiative for National Diabetes Awareness Month.

The initiative sees Abbott take over the Oculus Center in New York City with an animated installation promoting diabetes awareness. This installation features the faces and stories of people impacted by diabetes, including comedian and talk show host Sherri Shepherd.

Shepherd, a diabetes advocate, uses Abbott’s FreeStyle Libre continuous glucose monitor (CGM) to manage her condition.

“Using a FreeStyle Libre sensor to monitor my glucose levels has helped me get a better grasp on my Type 2 diabetes and ultimately improve my quality of living,” said Shepherd. “Many people living with diabetes aren’t aware of this incredible life-changing technology and Abbott’s efforts to make it accessible. The goal of ‘Countdown at a Crossroads’ is to change that – and I am energized to help by fostering awareness.”

How Abbott’s technology helps manage diabetes

Abbott said in a news release that, while more than 500 million adults live with diabetes in the world, only 1% use CGM technology. The company wants to raise awareness around its FreeStyle Libre technology and how it can help manage the condition.

FreeStyle Libre offers real-time data to help manage glucose levels and reduce HbA1c. A recent Abbott analysis also showed that, with the rising popularity of GLP-1 medications, these drugs can work better with CGMs. They not only aid in weight loss but create long-term behavior changes that help manage diabetes.

Abbott said it prices its CGM at 70% lower costs than other similar options, making it “the most affordable option” for Americans with diabetes.

“We purposefully made FreeStyle Libre technology to be accessible and affordable,” said Jared Watkin, SVP of Abbott’s Diabetes Care business. “However, even with our millions of users, we know that continuous glucose monitors are still not being used by the vast majority of people who can benefit from them. We’re working hard to spread awareness and improve access, and we hope that our critical innovation can play a part in slowing the diabetes epidemic.”

About the Countdown at a Crossroads initiative

Abbott chose the Oculus Center because it marks what it calls “the literal ‘Crossroads of the World.'” The structure on display at the Oculus Center will generate a different face of someone impacted by diabetes every 23 seconds. Visitors can also scan a QR code to learn more about diabetes, CGM and more.

The company said that, for very person who visits www.Crossroads.Abbott during November’s National Diabetes Awareness Month, it will provide a 99¢ donation to the American Diabetes Association’s Health Equity Now program.

“Our ongoing partnership with Abbott underscores the importance of making diabetes care and management accessible,” said Charles Henderson, CEO of the American Diabetes Association. “We appreciate Abbott’s support to increase awareness of health disparities and implement consumer access solutions during this critical time in the diabetes community. It takes all of us working together to end diabetes.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott

IN CASE YOU MISSED IT

  • Abbott partners with Berry Street to add nutrition coaching to Lingo
  • Dexcom CFO to expand into COO role
  • Beta Bionics insulin patch pump scores FDA clearance
  • Medtronic moves to divest final stake in MiniMed
  • Dexcom adds former Stryker CFO to board

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS